Nanomedicine Strategic Research and Innovation Agenda – ETPN SRIA Patrick Boisseau, ETPN Chairman, CEA-Leti, France ETPN Annual Event– 15.10.2014 – San Sebastian, Spain The next strategic step for the ETPN Vision 2005 SRA 2006 Roadmap 2009 SRIA 2014 White Paper 2013 ETPN Annual event 2014 – Nanomedicine SRIA 2 SRIA: Aims and Ambition • Vision of ETPN for the future development of nanomedicine • Main research and innovation priorities to be implemented under Horizon2020 and beyond Critical update of 2009 Roadmaps/ strategic priorities (KETs) Introduce Innovation in the SRA, translation tools and challenges Proposals for EC Workprograms 2018-2020 ETPN Annual event 2014 – Nanomedicine SRIA Foreseen SRIA structure Strategic • Pipeline • FP6-FP7 analysis • Hot and white spots • Overall Matrice State of the Art Research priorities • Selected diseases • Roadmaps by area • Cross-KET approach Fostering Development • White Paper update Effective Translation to support innovation • Business opportunities • Strategic collaborations • International strategy ETPN Annual event 2014 – Nanomedicine SRIA • Action Plan under H2020 • Timeframe H2020 WHAT HAS BEEN DONE ETPN Annual event 2014 – Nanomedicine SRIA 5 Building the SRIA: What has been done SRIA online survey 2016-2017 proposals ExBo Meeting April-14 Opening/second phase of the survey Consolidation for final recommendations Secretariat Survey analysis Analysis of NM projects under FP6-FP7 Consolidation of raw Pipeline Raw Structure of the Document Definition of Strategic priorities by area of applications ETPN Annual event 2014 – Nanomedicine SRIA Online Survey outcomes - Quick Facts Overall 299 answers received online – 183 eligible + 30 from Clinical WG Survey 137 relevant / 164 Technologies submitted 1,2 techno/answer on average 140 organisations Distribution of technological inputs by stakeholders Phase II Phase I 4% 15% 4% 1% Overall 15% 2% 3% 1% 76% Academia/Research Institute SME (under 250 employees) Large Industry Network, association or other support structure (platform, cluster...) 78% 1% Repartition of Technological inputs by application area Phase I 11% Phase II 9% 7% Overall 9% 10% 13% 49% 23% 31% Therapeutics Diag&Imaging RegMed Others 57% 28% 53% Analysis of FP6-FP7 nanomedicine projects 590 Mio € under FP7 et 125 Mio € identified under FP6 30 calls FP7-NMP and 10 FP7-Health answered with nanomedicine proposals 450 Mio € budget under NMP, 53 Moi € under Health Industrial participation: around 400 industrial participants (incl. SMEs) Consolidating the Nanomedicine Pipeline 122 PRODUCTS IN CLINICAL DEVELOPMENT • 57% in oncology • 14% in phases II/III et III ETPN Annual event 2014 – Nanomedicine SRIA 11 230 NANOPRODUCTS • 165 drugs et 65 medical devices • 70% of products in the four areas of oncology, infectious diseasses, cardiovascular and orthopaedics ETPN Annual event 2014 – Nanomedicine SRIA 12 NEXT STEPS ETPN Annual event 2014 – Nanomedicine SRIA 13 Building the SRIA: Final Steps ETPN Event 2014 Consolidation of technical inputs Mid October ExBo / Secretariat SRIA Document First Final Draft early December ETPN Annual event 2014 – Nanomedicine SRIA Official release End of 2014 Building the overall Matrice: Linking nanomed KETs and unmet medical needs Nanomedicine cross-KET Technologies Nanomedicine Pipeline - Commercial products - Under clinical development Function Potential applications & Benefits Societal and healthcare challenges Unmet Medical needs per key pathology Empty pockets, unforeseen technologies ETPN Annual event 2014 – Nanomedicine SRIA Building the overall Matrice: Linking nanomed KETs and unmet medical needs(2) Tech 1 Application 1 Unmet need 1 Tech 2 Application 2 Unmet need 2 Tech 3 Application 3 Unmet need 3 Application 4 Unmet need 4 Tech 4 ETPN Annual event 2014 – Nanomedicine SRIA Building the Strategic priorities ETPN Event 2014 WG Meetings ETPN Annual event 2014 – Nanomedicine SRIA ETPN RECOMMENDATIONS FOR 2016-2017 ETPN Annual event 2014 – Nanomedicine SRIA 19 Consultation processes Collaborative Horizontal topics ETP SRA Temporary Working Group on „Medical devices“ ETPN Roadmap RegMed Therapeutics Strategic Diag & Imaging Internal ETPN Executive Board ETPN White Paper Nanomedical R&I Topics WP 2016/2017 ETPN Annual event 2014 – Nanomedicine SRIA 21 28 propositions for calls formulated 2 HEALTH-ICT 2 NMP-HEALTH 1 HEALTH-INFRA 23 Research and Innovation Actions 3 NMP-ICT 10 NMP 4 Coordination and Support Actions ETPN Annual event 2014 – Nanomedicine SRIA 10 ICT 1 ERA-NET COFUND 22 NMP Related topics Nb Title Priority Application TRL 01 Nanoformulation of biologicals A Therapeutics 1-3 to 4 02 Innovative approaches to design and assess the effectiveness of vaccine formulations A Therapeutics 3 to 5 03 Science to reduce the cost of nucleic acids for nanomedicines B Therapeutics 2 04 3D-tissue printing of materials and living cells on a micro- and nanoscale to enable printing of complex functional tissue on a large scale B Regenerative Medicine 4 05 Nanotechnologies for imaging cellular transplants and regenerative processes in vivo with focus on preclinical large animal models A Regenerative Medicine 3 06 New Medical adhesives and sealants for novel applications A 07 Innovative activable nano objects to become the active principle B 08 Support translation of nano-enabling technologies to the late development stages A All - 09 Mobilising the European nano-biomedical ecosystem A All - 10 ERA-NET on Nanomedicine (Call 2017) A All - ETPN Annual event 2014 – Nanomedicine SRIA Regenerative Medicine TherapeuticsDiagnostics 3 to 5 3-4 to 6 23 Multi-KETs topics Nb Title Directorate Priority Application TRL 01 Wearable and implantable patches with combined biochemical monitoring and drug delivery NMP-ICT A Therapeutics Diagnostics 2 to 6 02 Nano-devices or robotic devices involving nanotechnology for the delivery of drugs in vivo NMP-ICT B Therapeutics 1 to 2 03 Nano-diagnostics devices for neurodegenerative diseases (incl. CNS) NMP-ICT B Diagnostics and Imaging 2 to 4 04 Nanobiomaterials and targeting systems: biofunctionalisation and novel coupling technologies NMP-HEALTH A Regenerative MedicineTherapeutics 4 05 Vaccine nanotechnology to improve oral allergy immunotherapy NMP-HEALTH B Therapeutics 6-7 to 8 06 Medical translation centres for an accelerated and safer translation of innovative medical devices HEALTHINFRA A All 4 to 6-7 07 “Organ-on-a-Chip” – accelerating clinical trials of new drugs and cell therapies with smart devices HEALTH-ICT A Therapeutics 2 to 5 08 Nano-based systems for assessing and monitoring therapy and rehabilitation effectiveness in chronic and degenerative diseases HEALTH-ICT B Therapeutics 1 to 4 ETPN Annual event 2014 – Nanomedicine SRIA 24 ICT Related topics Nb Title Priority TRL 01 “Flight Simulator”-like system for surgical mission rehearsal to prevent avoidable medical errors A 3-4 to 6 02 Smart prosthetics A 3 to 5 03 Imaging-guided drug delivery of nano-sized systems for personalized therapeutic treatments of solid tumours A 3 to 6 04 Advanced nanosensors and nano-enabled platforms for new smart medical devices and systems B 3 to 8 05 Human body condition monitoring A 2 to 5 06 Towards energy-autonomous smart medical devices A 3 to 6 07 Multiscale integration at the biointerface B 3 to 6 08 Beyond laboratory proofs of concept: Prototyping and manufacturing of small series of medical devices for pre- or clinical validation A 4 to 6-7 09 Translate by design: integrating users’ requirements in designing smart Medical Devices A - 10 Fostering innovation in the smart medical devices sector, by networking, advising, training and coaching A - ETPN Annual event 2014 – Nanomedicine SRIA 25 CURRENT OVERVIEW OF NANOMEDICINE UNDER H2020 ETPN Annual event 2014 – Nanomedicine SRIA 28 Nanomedicine under Horizon2020 – past calls Calls Horizon 2020 - ICT Deadline ICT 2 – 2014: Smart System Integration including heterogeneous integration Type of Funding Budget Research & Innovation 23/04/2014 Actions 35 Mio. € for ICT-2 a) (100% funding) of micro and nanotechnologies Horizon 2020 - PHC PHC 10 – 2014: Development of new diagnostic tools Stage 1 – 11/03/2014 Research and innovation and technologies: in vitro devices, Stage 2 – 19/08/2014 actions (100% funding) Stage 1 – 11/03/2014 Research and innovation Stage 2 – 19/08/2014 actions (100% funding) 4-6 Mio. € per proposal assays and platforms PHC 13 – 2014: New therapies for chronic noncommunicable diseases 4-6 Mio. € per proposal Horizon 2020 - NMP NMP 8 – 2014: Scale-up of nanopharmaceuticals production NMP 9 – 2014: Networking of SMEs in the nanobiomedical sector Single stage Deadline 06/05/2014 Single stage Deadline 06/05/2014 Research & Innovation 5-8 Mio. € per proposal Actions (funding Rate: (66.20 Mio € allocated for topics 100%) NMP 1,4,5,8) Coordination & Support 1-2 Mio. € per proposal Action (12.50 Mio. € allocated for topics (funding Rate: 100%) NMP 9,27,31,33,34,36,37,38,39) 2-stage submission Research & Innovation Deadline 1st Actions (funding Rate: NMP 10 – 2014: stage: 100%) Biomaterials for the treatment of 06/05/2014 (114.20 Mio. € allocated for topics Deadline 2nd NMP 10,13,18,20,21,26,28,35) diabetes mellitus 6-8 Mio. € per proposal stage: 07/10/2014 ETPN Annual event 2014 – Nanomedicine SRIA 29 Nanomedicine under Horizon2020 (2) ETPN Annual event 2014 – Nanomedicine SRIA 30 Looking forward to serving the nanomedicine community Thank you for attention! For more information, contact: [email protected]
© Copyright 2024 ExpyDoc
